Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,712 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Muscle Disorders Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Insulin Resistance
Interventions: VO2 Max, DEXA, Peripheral Microvascular Reactivity, Skeletal Muscle Insulin Sensitivity, Non-Oxidative Glucose Disposal, Muscle tissue Biopsy; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 30 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Sarcopenia
Interventions: Tadalafil 5mg; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 60 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Breast Cancer, Musculoskeletal Complications, Pain
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 714
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more

Conditions: Obesity, Pre-diabetes
Interventions: 9 hours daily eating window, 15 hours daily eating window; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years to 70 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Davis, California

Conditions: Osteoporosis, Sarcopenia
Interventions: Potassium Bicarbonate, Sodium Bicarbonate, Potassium Chloride, placebo (microcrystalline cellulose); Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 50 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Muscle Invasive Bladder Cancer
Interventions: Nivolumab, Cisplatin, Gemcitabine; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Salt Lake City, Utah

Conditions: Cerebral Palsy, Spasticity
Interventions: IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight); Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more

Conditions: Low Back Pain, Musculoskeletal Pain, Low Back Injury
Interventions: Back Exosuit; Device
Lead sponsor: Wyss Institute at Harvard University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: CAP-1002, Placebo; Biological · Drug
Lead sponsor: Capricor Inc.; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Sacramento, California • Aurora, Colorado • Orlando, Florida + 6 more

Conditions: Musculoskeletal Pain
Interventions: Emotional Awareness and Expression Therapy, Cognitive Behavior Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 95 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Arthritis, Joint Pain, Muscle Pain, Musculoskeletal Pain, Joint Stiffness
Interventions: Intervention (Saje Pain Release Joint & Arthritis Cream), Placebo Comparator; Dietary Supplement
Lead sponsor: Saie Beauty; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Sarcopenia
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 70 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Peripheral Artery Disease
Interventions: Leg heat therapy, Sham Control; Device
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, RISS Stage I Multiple Myeloma, RISS Stage II Multiple Myeloma, RISS Stage III Multiple Myeloma
Interventions: Questionnaire Administration, Biospecimen Collection; Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 40 Years to 75 Years
Enrollment: 2,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 747
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 502 more

Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions: Not listed
Lead sponsor: xCures; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Altos, California

Conditions: MItochondrial Myopathies, Mitochondrial Disease
Interventions: Nanosensor; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lateral Epicondylitis, Unspecified Elbow
Interventions: Embozene particles; Device
Lead sponsor: Siddharth Padia, MD; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tennis Elbow
Interventions: Dextrose prolotherapy, PrT-DMS, Platelet Rich Plasma injection; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Bladder Cancer
Interventions: Gemcitabine and Cisplatin (DD GC); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 4 more

Conditions: Fibromyalgia
Interventions: Tramadol, Placebo, Cognitive Behavior Therapy for FM, Health Education; Drug · Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 70 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Rochester, New York • Seattle, Washington

Conditions: Cardiovascular Diseases
Interventions: Blood volume collected specifically for this study; Biological
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 50 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Muscle Spasticity
Interventions: Hyaluronidase, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Secondary Dysmenorrhea, Dysmenorrhea, Dysmenorrhea Secondary, Polycystic Ovary Syndrome, Endometriosis, Fibroid, Menstrual Pain, Menstrual Disorder, Menstrual Discomfort
Interventions: Iyengar Yoga Therapy; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 12 Years to 65 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Urbana, Illinois

Search by objective public record fields.

Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans

Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance

Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

The Effect of Time-Restricted Eating in Cardiometabolic Health

Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

Soft Active Back Exosuit to Reduce Workplace Back Pain

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Optimizing Psychotherapy for Older Veterans With Chronic Pain

A Controlled Study to Evaluate the Effects of a Topical Cream on Symptoms of Arthritis, Joint, and Muscle Pain

Evaluation of the Reproducibility of Jumping Mechanography

Leg Heat Therapy in Peripheral Artery Disease

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Validation of Nanosensor Oxygen Measurement

Elbow Artery Embolization for Tennis Elbow

Efficacy of Injection Therapy for Lateral Epicondylosis

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Combined Behavioral and Analgesic Trial for Fibromyalgia

The Role of the Space Environment on Vascular Endothelial and Smooth Muscle Cell Processes

Peripheral Modulation of Muscle Stiffness and Spasticity

Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis